Premium
Microdosing of protein drugs
Author(s) -
Rowland M
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.275
Subject(s) - microdose , pharmacokinetics , pharmacology , medicine , clinical trial , recombinant dna , chemistry , biochemistry , gene
Poor pharmacokinetics (PK) can seriously limit clinical utility. Knowing early whether a new compound is likely to have the desired PK profile at therapeutic doses is therefore important. One approach, microdosing,[1][Lappin, G., 2003] has shown high success with small molecular weight compounds,[2][Lappin, G., 2013] despite early skepticism. Vlaming et al .[3][Vlaming, M.L.H., 2015] report the first, and successful, clinical application of a microdose of a humanized recombinant protein. But what is the likely success for this class of drugs more generally?